NurX CEO Varsha Rao joins host Jonah Comstock and MobiHealthNews Managing Editor Laura Lovett to discuss her telehealth company's journey from a laser focus on contraception to a broader play for women's (and men's) health that includes dermatology and migraines.
Along the way, we also discuss broader trends in telehealth, the challenges of femtech and NurX's foray into COVID-19 testing.
Like what you hear? Subscribe to the podcast on Apple Podcasts, Spotify or Google Play!
Talking points:
- NurX’s story
- What does it mean to be a female-focused telehealth company?
- Following a patient through their lifelong patient journey
- How NurX got into home COVID-19 testing
- Digital health companies as service companies
- Challenges and advantages of a woman-led startup
- Things men don’t understand about contraception
- NurX’s road map for new products, and COVID-19’s effect on it
- Should telehealth be a one-stop shop?
- The advantages of asynchronous telemedicine
- Dealing with stigma in healthcare
- The future of digital health and telehealth
- NurX’s role in COVID-19 testing
- What’s next for NurX?
- Varsha’s advice for healthcare startups
More about this episode:
Nurx CEO on what's next for women's health in 2021
Nurx sets sights on the migraine and headache space
Nurx collects another $22.5M for birth control & STI treatment deliveries
At-home COVID-19 testing services pump the brakes after FDA warns of 'fraudulent' kits
EverlyWell, Nurx to release at-home COVID-19 test kits within a week
Nurx gets another $52 million to deliver mail-order birth control, PrEP, STI test kits
Nurx adds STI testing to its mail-order product suite
Nurx gets $36M for telemedicine for birth control, adds Chelsea Clinton to board
Nurx raises $5.3M for app-based birth control and PrEP service
